pimobendan has been researched along with dihydropyridines in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endoh, M | 2 |
| Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R | 1 |
2 review(s) available for pimobendan and dihydropyridines
| Article | Year |
|---|---|
[Ca2+ sensitizers].
Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dihydropyridines; Drug Design; Heart Failure; Humans; Hydrazones; Myocardium; Pyridazines; Signal Transduction; Simendan | 2000 |
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C | 2008 |
1 other study(ies) available for pimobendan and dihydropyridines
| Article | Year |
|---|---|
Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
Topics: Administration, Oral; Animals; Calcium; Cardiotonic Agents; Dihydropyridines; Dilatation, Pathologic; Disease Models, Animal; Dogs; Echocardiography; Female; Heart Failure; Heart Ventricles; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridazines; Stimulation, Chemical; Systole | 2014 |